The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
Abstract
OBJECTIVE: The authors conducted a dose-finding study of D-cycloserine, a partial agonist at the glycine site of the N-methyl-D-aspartate subtype of the glutamate receptor, added to conventional neuroleptics for schizophrenic patients with prominent negative symptoms. METHOD: Nine patients with schizophrenia completed consecutive 2-week trials of placebo and four doses of D-cycloserine. Clinical assessments were videotaped and were scored by a rater who was blind to temporal sequence. RESULTS: D-Cycloserine at a dose of 50 mg/day produced a significant reduction (mean = 21%, SD = 28%) in negative symptoms and significantly improved reaction time as measured by Sternberg's Item Recognition Paradigm, a test mediated in part by prefrontal cortex. CONCLUSIONS: This preliminary evidence suggests that D-cycloserine may improve negative symptoms and cognitive deficits over a narrow dose range when added to conventional antipsychotic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Cited by
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
“Goff et al. (1995) used the partial GMS agonist, D-cycloserine, which crosses the blood brain barrier, in an initial dose finding study and observed a U-shaped dose response curve with improvement in negative symptoms and reduction in cognitive impairments at a dose of 50 mg/day.”
MethodSelf-citationThe Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
Danysz, W., & Parsons, C. G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01382-6 · Cited by 649
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Glutamatergic mechanisms in schizophrenia
Tsai, G., & Coyle, J. T. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082701.160735 · Cited by 577
Self-citationD-serine added to antipsychotics for the treatment of schizophrenia
Tsai, G., Yang, P., Chung, L.-C., Lange, N., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 571
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568
Self-citationKrystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia
COYLE, J. T., TSAI, G., & GOFF, D. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.020 · Cited by 442
Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
Glutamate receptor expression in schizophrenic brain
Meador-Woodruff, J. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00044-2 · Cited by 412
Modulation of N -methyl- d -aspartate receptor function by glycine transport
Bergeron, R., Meyer, T. M., Coyle, J. T., & Greene, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15730 · Cited by 411
NMDA Receptor and Schizophrenia: A Brief History
Coyle, J. T. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs076 · Cited by 410
Should Schizophrenia Be Treated as a Neurocognitive Disorder?
Green, M. F., & Nuechterlein, K. H. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033380 · Cited by 402
Heresco-Levy, U., Javitt, D. C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S., & Ermilov, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.037 · Cited by 386
Consolidation of Human Motor Cortical Neuroplasticity by D-Cycloserine
Nitsche, M. A., Jaussi, W., Liebetanz, D., Lang, N., Tergau, F., & Paulus, W. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300517 · Cited by 385
Manoach, D. S., Press, D. Z., Thangaraj, V., Searl, M. M., Goff, D. C., Halpern, E., Saper, C. B., & Warach, S. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00318-7 · Cited by 384
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336
The NMDA Receptor and Schizophrenia
Balu, D. T. (2016) · Advances in Pharmacology · doi:10.1016/bs.apha.2016.01.006 · Cited by 285
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.5.610 · Cited by 255
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D. C. (2004) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00707-8 · Cited by 222
Prepulse inhibition and genetic mouse models of schizophrenia
Powell, S. B., Zhou, X., & Geyer, M. A. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.04.021 · Cited by 218
“D-cycloserine has been shown to improve negative symptoms when added to antipsychotic therapy in some clinical trials [72,73], but failed to show improvement in other trials [71,206].”
ResultThe NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond
Balu, D. T., & Coyle, J. T. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.12.004 · Cited by 208
Self-citationMarx, C. E., Keefe, R. S. E., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.26 · Cited by 193
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
“1998), glycine B receptor agonists (Goff et al. 1995; Tsai and Lin 2010), mGluR5 agonists (Conn et al.”
BackgroundSelf-citationGOFF, D., CATHER, C., GOTTLIEB, J., EVINS, A., WALSH, J., RAEKE, L., OTTO, M., SCHOENFELD, D., & GREEN, M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.012 · Cited by 144
“Previous trials employing daily dosing in schizophrenia also failed to produce cognitive benefit at 8 weeks (Goff et al., 1999b, 2005) although one trial found improvement on Sternberg's Item Recognition Task after 2 weeks of daily dosing with D-cycloserine 50 mg (Goff et al., 1995).”
Self-citationCircuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia†
Greene, R. (2001) · Hippocampus · doi:10.1002/hipo.1072 · Cited by 140
“The discovery of glycine (Johnson and Ascher, 1987; Klecker and Dingledine, 1988) as a necessary coagonist suggests one possible means, the administration of glycine or its partial agonist, D-cycloserine (Javit et al., 1994; Goff et al., 1995).”
BackgroundD-Cycloserine in Neuropsychiatric Diseases: A Systematic Review
Schade, S., & Paulus, W. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv102 · Cited by 135
Drug targets for cognitive enhancement in neuropsychiatric disorders.
Wallace, T. L., Ballard, T. M., Pouzet, B., Riedel, W. J., & Wettstein, J. G. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.022 · Cited by 127
Apathy in schizophrenia: clinical correlates and association with functional outcome
Kiang, M., Christensen, B. K., Remington, G., & Kapur, S. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00433-4 · Cited by 118
The neuroanatomy of schizophrenia: circuitry and neurotransmitter systems
Fallon, J. H., Opole, I. O., & Potkin, S. G. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00022-7 · Cited by 53
Otto, M. W., Basden, S. L., Leyro, T. M., McHugh, R. K., & Hofmann, S. G. (2007) · CNS Spectrums · doi:10.1017/s1092852900020526 · Cited by 53
Dauvermann, M. R., Whalley, H. C., Romaniuk, L., Valton, V., Owens, D. G. C., Johnstone, E. C., Lawrie, S. M., & Moorhead, T. W. J. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.01.063 · Cited by 49
“This suggests that glutamate neurotransmission, specifically NMDA receptor-mediated transmission, may be disrupted in schizophrenia (Goff and Coyle, 2001; Goff et al., 1995; Javitt et al., 1994; Moghaddam et al., 1997).”
BackgroundTreatment of Comorbid Tuberculosis and Depression
Trenton, A. J., & Currier, G. W. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0610 · Cited by 48
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1995-08-01
- Volume
- 152
- Issue
- 8
- Pages
- 1213-1215
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W52175841
- Cited by
- 243
- References
- 5
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.